Spirax-Sarco Engineering (SPX.L) is a UK-based global leader in steam system management, heat transfer, and peristaltic pumping. The company operates through three segments: Steam Specialties, Electric Thermal Solutions (ETS), and Watson-Marlow Fluid Technology Group (WMFTG). Despite a challenging macroeconomic environment in 2023-2024, the company has maintained its market leadership and is now poised for a cyclical recovery.
Investment Thesis
Spirax-Sarco benefits from secular trends in energy efficiency and industrial automation. Steam systems account for a significant portion of global industrial energy use, and Spirax’s products help customers reduce energy consumption by up to 20%. With rising energy costs and tightening environmental regulations, demand for steam system optimization is structurally growing. The company’s high recurring revenue base (over 60% from aftermarket services and consumables) provides earnings visibility and resilience.
12-Month Catalysts
- Margin Recovery: After a period of cost inflation and supply chain disruption, Spirax is implementing price increases and productivity measures. We expect operating margins to expand from ~19% in 2025 to over 21% by 2027, driving earnings growth.
- Watson-Marlow Turnaround: The WMFTG segment, which serves biopharma and food & beverage, has been in a cyclical downturn. With bioprocessing demand stabilizing and new product launches, we anticipate a return to growth in H2 2026.
- Energy Efficiency Regulation: The UK and EU are tightening industrial energy efficiency standards, which should accelerate replacement cycles and new installations for Spirax’s steam solutions.
Key Risks
- Industrial Recession: A deeper global industrial downturn could delay the recovery in WMFTG and pressure volumes in Steam Specialties.
- Currency Headwinds: Spirax generates over 80% of revenue outside the UK, so a strong GBP could negatively impact reported earnings.
Valuation
At ~25x forward P/E, Spirax trades at a premium to the UK market but at a discount to its 5-year average of 30x. With EPS expected to grow at a 10% CAGR over the next three years, the PEG ratio is below 1.5, offering a reasonable entry point for a high-quality compounder.
Balance Sheet
Net debt to EBITDA is ~1.5x, well within the company’s target range. Free cash flow conversion is strong at over 90%, supporting a progressive dividend policy and bolt-on acquisitions.
Disclaimer: This is not financial advice. Investing involves risk, including loss of principal. Do your own research.